Search - tctmd.com

Displaying 1 - 9 of 9

Sort: Relevancy | Date

News Industry News

TherOx Enrolls First Patient in Study of Next-Generation Supersaturated Oxygen Therapy for AMI

February 17, 2016

News Industry News

TherOx Receives FDA IDE Approval for Study of Next-Generation Supersaturated Oxygen Therapy for AMI

November 04, 2015

News Industry News

Ventrix Initiates Clinical Trial of VentriGel™

September 17, 2015

News Industry News

US FDA Approves Expanded Indication For Brilinta To Include Long-term Use In Patients With a History of Heart Attack

September 03, 2015

News Industry News

Zebra Technologies Introduces Smart, Non-Invasive Way for Hospitals to Track, Provide Real-Time Feedback on Patients with Acute Myocardial Infarction

August 26, 2015

News Industry News

New Analyses from the IMPROVE-IT Outcomes Study of VYTORIN® (ezetimibe and simvastatin) and the TECOS Cardiovascular Safety Trial of JANUVIA® Will Be Presented at the European Society of Cardiology

August 20, 2015

News Industry News

New Cost Effectiveness Model Underlines Scope of Polypill Strategy to Prevent Recurring Cardiovascular Events and for More Efficient Use of Health Budgets

June 19, 2015

News Industry News

First CVD Outcome Trial of a GLP-1 Agonist Finds No Cardiac Risk or Benefit

June 09, 2015

News Industry News

Takeda Presents Additional Data from Alogliptin's EXAMINE Cardiovascular Safety Outcomes Trial at the American Diabetes Association's 75th Scientific Sessions

June 05, 2015

Advertisement

TherOx Enrolls First Patient in Study of Next-Generation Supersaturated Oxygen Therapy for AMI

TherOx Receives FDA IDE Approval for Study of Next-Generation Supersaturated Oxygen Therapy for AMI

Ventrix Initiates Clinical Trial of VentriGel™

US FDA Approves Expanded Indication For Brilinta To Include Long-term Use In Patients With a History of Heart Attack

Zebra Technologies Introduces Smart, Non-Invasive Way for Hospitals to Track, Provide Real-Time Feedback on Patients with Acute Myocardial Infarction

New Analyses from the IMPROVE-IT Outcomes Study of VYTORIN® (ezetimibe and simvastatin) and the TECOS Cardiovascular Safety Trial of JANUVIA® Will Be Presented at the European Society of Cardiology

New Cost Effectiveness Model Underlines Scope of Polypill Strategy to Prevent Recurring Cardiovascular Events and for More Efficient Use of Health Budgets

First CVD Outcome Trial of a GLP-1 Agonist Finds No Cardiac Risk or Benefit

Takeda Presents Additional Data from Alogliptin's EXAMINE Cardiovascular Safety Outcomes Trial at the American Diabetes Association's 75th Scientific Sessions

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content